Illumina announces acquisition of Epicentre Biotechnologies

Illumina, Inc. today announced that it has acquired Epicentre Biotechnologies, a leading provider of nucleic acid sample preparation reagents and specialty enzymes used in sequencing and microarray applications. A key component of the acquisition is direct access to Epicentre's proprietary Nextera™ technology for next-generation sequencing library preparation, which greatly simplifies genetic analysis workflows and reduces time from sample preparation to answer.

“As next-generation sequencing continues to improve in throughput and cost, there's a critical need for sample prep to evolve as well, to lower costs, handle higher sample volumes and reduce both hands-on and overall processing time”

"As next-generation sequencing continues to improve in throughput and cost, there's a critical need for sample prep to evolve as well, to lower costs, handle higher sample volumes and reduce both hands-on and overall processing time," said Jay Flatley, President and CEO of Illumina. "Epicentre's Nextera technology provides a step-change improvement in library prep that will translate into greater ease of use, lower costs, and faster turnaround times for sequencing applications. In addition to Nextera, Epicentre is a leading supplier of specialty enzymes and kits that are beneficial to Illumina's technologies."

The rapid adoption of Nextera sequencing sample prep kits by existing Illumina sequencing customers is indicative of the cost effectiveness, ease of use, and efficiency of Nextera technology. With this patented technology, researchers can prepare sequencer-ready libraries from genomic DNA with less than 15 minutes of hands-on time - a significant timesaving compared to alternate methods. In addition, Nextera technology requires 10-100 times less starting DNA, which enables applications with limited starting material such as tumor biopsies, degraded DNA, or purified RNA. These unique features of Nextera sequencing library prep kits are all critical to advancing the evolution of next-generation sequencing.

The combined company will be uniquely positioned to offer an end-to-end solution for next-generation sequencing, microarray, and real time PCR applications. Epicentre's unique capabilities in enzyme engineering and sample preparation reagent development will complement Illumina's core platform expertise to comprehensively address the needs of researchers across their entire genetic analysis workflow.

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Illumina, Inc.. (2019, June 18). Illumina announces acquisition of Epicentre Biotechnologies. News-Medical. Retrieved on October 31, 2024 from https://www.news-medical.net/news/20110112/Illumina-announces-acquisition-of-Epicentre-Biotechnologies.aspx.

  • MLA

    Illumina, Inc.. "Illumina announces acquisition of Epicentre Biotechnologies". News-Medical. 31 October 2024. <https://www.news-medical.net/news/20110112/Illumina-announces-acquisition-of-Epicentre-Biotechnologies.aspx>.

  • Chicago

    Illumina, Inc.. "Illumina announces acquisition of Epicentre Biotechnologies". News-Medical. https://www.news-medical.net/news/20110112/Illumina-announces-acquisition-of-Epicentre-Biotechnologies.aspx. (accessed October 31, 2024).

  • Harvard

    Illumina, Inc.. 2019. Illumina announces acquisition of Epicentre Biotechnologies. News-Medical, viewed 31 October 2024, https://www.news-medical.net/news/20110112/Illumina-announces-acquisition-of-Epicentre-Biotechnologies.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
NovaSeq, the new sequencer by Illumina, said to transform the field of genomics